NDAINJECTIONINJECTABLEPriority Review
Approved
Jun 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
OCTREOSCAN (indium in -111 pentetreotide) by Curium Pharma is clinical pharmacology general pentetreotide is a dtpa conjugate of octreotide, which is a long-acting analog of the human hormone, somatostatin. First approved in 1994.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OCTREOSCAN is an indium-111 labeled diagnostic imaging agent based on pentetreotide, a somatostatin receptor-binding peptide analog. It is used for scintigraphic localization of primary and metastatic neuroendocrine tumors that express somatostatin receptors. The drug works by binding to somatostatin receptors on tumor cell surfaces, allowing visualization of receptor-rich tissue after background clearance.
LOE Approaching
Product is approaching loss of exclusivity with low linked job count (0), indicating a mature, stable commercial team with limited growth expansion opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY General Pentetreotide is a DTPA conjugate of octreotide, which is a long-acting analog of the human hormone, somatostatin. Indium In 111 pentetreotide binds to somatostatin receptors on cell surfaces throughout the body. Within an hour of injection, most of the dose of indium…
Worked on OCTREOSCAN at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.